Core Viewpoint - Flora Growth Corp. has announced the withdrawal of its proposed public offering of common shares [1] Company Overview - Flora Growth Corp. is set to be rebranded as ZeroStack and is the first Nasdaq-listed asset management company focused on decentralized AI [3] - The company operates a global pharmaceutical distribution business through its wholly owned subsidiary, Phatebo GmbH [3]

Toronto, Ontario--(Newsfile Corp. - January 27, 2026) - Flora Growth Corp. (NASDAQ: FLGC) (the "Company"), today announced it has commenced an underwritten public offering of its common shares. All common shares in the offering are to be offered by the Company. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.R.F. Lafferty & Co., Inc. is acting as the sole book-running manager f ...

Core Viewpoint - Pharmaceutical distributors, traditionally viewed as low-margin utilities, are evolving, with Cencora (COR) indicating a shift in operational strategy to potentially enhance profitability and service offerings [1] Industry Summary - The pharmaceutical distribution sector has been characterized by low margins, primarily serving the volume-driven needs of the healthcare industry [1] - Cencora has historically operated within this low-margin framework but is now exploring new operational strategies [1]

CHICAGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced continued operational growth and infrastructure expansion at Cosmofarm, its pharmaceutical distribution subsidiary in Greece. During 2025, Cosmofarm added nearly 100 new pharmacy customers, representing a weighted average increase of approximately 20% in its active customer base. This growth was accompanied by improved u ...

Core Insights - The article emphasizes that while sales and earnings are important metrics for evaluating a company, they may not be sufficient for long-term investment decisions. A deeper analysis of a company's financial health and stability is necessary for sustainable growth [1] Financial Analysis - A critical analysis of a company's financial background is essential for informed investment decisions, with coverage ratios being a key focus. The Interest Coverage Ratio is highlighted as a crucial indicator of a company's ability to meet its debt interest obligations [2][4] - The Interest Coverage Ratio is calculated as Earnings before Interest & Taxes (EBIT) divided by Interest Expense, and companies like Amazon, Stride, Brinker International, and Cardinal Health have strong ratios [3] Importance of Interest Coverage Ratio - The Interest Coverage Ratio indicates how effectively a company can pay interest on its debt, with a ratio below 1.0 suggesting potential default risks. Companies generating earnings significantly above their interest expenses are better positioned to withstand financial difficulties [5][7] Investment Strategy - A winning investment strategy includes selecting stocks with an Interest Coverage Ratio above the industry average, a favorable Zacks Rank, and a VGM Score of A or B, which can lead to better investment outcomes [8][11] - Stocks that meet criteria such as a minimum price of $5, strong historical and projected EPS growth, and substantial trading volume are more likely to perform well [9][11] Company Performance - Amazon has a Zacks Rank of 2, a VGM Score of B, and a trailing four-quarter earnings surprise of 22.5%, with projected sales and EPS growth of 12% and 29.7% respectively [10][12] - Stride also holds a Zacks Rank of 2 and a VGM Score of B, with projected sales and EPS growth of 4.6% and 3.1% respectively, despite a stock decline of 38.8% over the past year [12][13] - Brinker International has a Zacks Rank of 2 and a VGM Score of A, with projected sales and EPS growth of 6.5% and 14.9% respectively, and a stock increase of 15.7% in the past year [13][14] - Cardinal Health leads with a Zacks Rank of 2 and a VGM Score of A, showing a stock performance increase of 69.1% and projected sales and EPS growth of 16.3% and 20% respectively [10][14][15]

Summary of Cardinal Health Conference Call Company Overview - **Company**: Cardinal Health - **Industry**: Healthcare Services - **CEO**: Jason Hollar - **CFO**: Aaron Alt - **Revenue**: Expected to exceed $250 billion in the current year [5][6] Key Financial Highlights - **Earnings Per Share (EPS)**: Expected to be at least $10 per share for fiscal 2026, driven by broad-based growth and strategic initiatives [3][14] - **Core Operating Earnings Growth**: Achieved a 14% CAGR over the last several years, translating into an 18% EPS growth [4] - **Adjusted Free Cash Flow**: Averaging over $3 billion, with a conversion rate of over 150% over the last three years [6] - **Pharmaceutical and Specialty Solutions Business**: Accounts for over 90% of revenue and nearly 80% of profit [6] Strategic Focus Areas - **Core Business**: Emphasis on pharmaceutical and specialty solutions, with a focus on organic and inorganic growth [15][16] - **At-Home Solutions**: Growth in this segment is seen as a strategic priority, with investments in technology and partnerships [11][60] - **GMPD (Medical Supply Division)**: Positioned as a turnaround business, with significant investments to improve performance and service levels [62][64] Market Dynamics - **Demographics**: Increasing number of Americans over 65 years old, leading to higher pharmaceutical utilization [10] - **Utilization Trends**: Strong demand across various product categories, with a focus on maintaining low unit costs [9][32] - **Pricing Environment**: Contractual ability to renegotiate prices in response to market changes, with a focus on maintaining margins [28][30] Growth Opportunities - **Specialty Areas**: Focus on autoimmune, urology, and oncology, with significant growth expected in these therapeutic areas [19][20] - **Biopharma Solutions**: Anticipated growth of over 30% in fiscal 2026, with plans to achieve $1 billion in revenue by fiscal 2028 [21][22] - **M&A Strategy**: Focus on tuck-in acquisitions to enhance existing capabilities, particularly in specialty areas [66][67] Risks and Challenges - **Regulatory Changes**: Potential impacts from CMMI demos and pricing changes related to Part B, but manageable due to the diversified payer mix [34][35] - **Market Competition**: Continuous investment in capabilities to maintain competitive advantage and customer relationships [13][40] Conclusion - **Overall Outlook**: Cardinal Health is positioned for continued growth with a strong focus on strategic initiatives, operational improvements, and market opportunities. The company remains committed to delivering value to shareholders while navigating industry challenges [68]

Core Viewpoint - Cardinal Health, Inc. has raised its fiscal 2026 earnings outlook, projecting non-GAAP diluted earnings per share to be at least $10, up from a previous range of $9.65 to $9.85, indicating improved operational performance [1] - The company expects Specialty revenues to exceed $50 billion during fiscal 2026, representing a 16% compounded annual growth rate over three years [2] Medicare Pricing Transition - Cardinal Health successfully transitioned pharmaceutical distribution agreements affected by the Medicare Drug Price Negotiation Program changes ahead of implementation, ensuring appropriate compensation for its distribution services [3] - The company introduced the ContinuCare Pathway program under its at-Home Solutions business to simplify diabetes supply management and insurance navigation for patients and partner pharmacies [4] Broad Business Scope - Cardinal Health is a major distributor of pharmaceuticals, specialty products, and medical and laboratory supplies, also providing performance solutions and direct-to-patient services across the healthcare sector [5] - At the time of publication, Cardinal Health shares rose by 4.08% to $210.77, trading near its 52-week high of $214.93 [5]

1 th DUBLIN, Ohio, Jan. 13, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today provided an update to its financial outlook for fiscal year 2026 and plans to highlight significant progress with its strategic growth initiatives during the 44 Annual J.P. Morgan Healthcare Conference. "Our team's execution against our strategic growth plan continues to deliver meaningful results, and as a demonstration of our confidence and momentum, we are pleased to again raise our expectations for fiscal year 2026," said ...

Group 1: Lockheed Martin Corporation - Lockheed Martin Corporation (NYSE:LMT) was highlighted as a final trade by Jim Lebenthal, partner at Cerity Partners [1] - Shares of Lockheed Martin rose 2.9% to close at $511.57 following the U.S. operation that seized former Venezuelan president Nicolás Maduro [5] - The company is set to release its fourth-quarter earnings results before the market opens on January 29 [1] Group 2: QXO, Inc. - QXO, Inc. (NYSE:QXO) announced a $1.2 billion convertible offering funded by Apollo, chosen as a final trade by Stephen Weiss, chief investment officer of Short Hills Capital Partners [2] - Shares of QXO jumped 18.2% to settle at $23.30 during the session [5] Group 3: McKesson Corporation - McKesson Corporation (NYSE:MCK) was selected as a final trade by Joe Terranova, senior managing director for Virtus Investment Partners [2] - Barclays analyst Glen Santangelo initiated coverage of McKesson with an Overweight rating and set a price target of $960 [3] - McKesson is expected to report quarterly earnings of $9.28 per share, up from $8.03 per share in the year-ago period, with projected quarterly earnings of $105.98 billion compared to $95.29 billion a year earlier [4] - Shares of McKesson gained 0.2% to close at $824.92 during the session [5]

Group 1 - Cardinal Health plans to release second-quarter financial results for fiscal year 2026 on February 5, prior to the opening of trading on the New York Stock Exchange [1] - A webcast discussion of these results will begin at 8:30 a.m. Eastern [1] - The webcast and corresponding slide presentation can be accessed on Cardinal Health's Investor Relations page without an access code [2] Group 2 - Cardinal Health is a distributor of pharmaceuticals and specialty products, a supplier of home-health and direct-to-patient products and services, and an operator of nuclear pharmacies and manufacturing facilities [3] - The company provides performance and data solutions and is a global manufacturer and distributor of medical and laboratory products [3] - Cardinal Health's customer-centric focus drives continuous improvement and leads to innovative solutions that improve people's lives [3]